We are thrilled to announce that InnoSer, as an innovative preclinical contract research organization (CRO) will be actively participating in the upcoming Society for Neuroscience 2024 Conference taking place in Chicago, US from Saturday 5th to 9th of October. ...
Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...
Preclinical epilepsy-related research with InnoSer Broadly speaking, epilepsy is a large spectrum of distinct epileptic syndromes that differ in their etiologies, mechanisms, pathophysiological processes, associated comorbidities, and response profile to available...
Charcot-Marie Tooth (CMT) disease is a hereditary, demyelinating peripheral neuropathy, leading to progressive muscle atrophy, weakness and subsequent walking disabilities and sensory impairments. Charcot-Marie Tooth Type 1A (CMT1A) is the most common type of CMT,...
Preclinical studies aiming to assess kidney function traditionally include readouts such as serum creatinine and/or blood urea nitrogen (BUN). However, the use of readouts that are more clinically relevant such as glomerular filtration rate (GFR) is highly encouraged,...
